stockrow

Screener

ANIXA BIOSCIENCES INC ANIX

Insider Buys alert about insiders buying in the last 12 month

Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.

Insider Decisions

Total buys

0.28

in millions of $

	Nov 25			Feb 26			May 26			Aug 26
Buy	—	—	—	1	—	—	—	—	2	8	—	3
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership

3.90%

Capital & Financial Ratios

Market Cap

95.60

Revenue

0.97

Net Income

(10.47)

Free Cash Flow

(7.38)

Net Debt

(13.86)

Current Ratio

8.55

Debt/Equity

0.00

P/E ratio

0.00

P/S ratio

97.41

P/B ratio

7.17

Past 5Y EPS Growth

7.73%

This Y EPS Growth

6.35%

Next Y EPS Growth

(1.08%)

Next 5Y EPS Growth

0.29%

in millions of $

Dividends

Payout Ratio

0.00

Annual Dividend Rate

—

Annual Dividend Yield

—

	total	individual payouts
2023	‡‡‡
2022	‡‡‡
2021	‡‡‡
2020	‡‡‡
2019	‡‡‡
2017	‡‡‡

predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

	2023	2024	2025	Q'26
Cash	23.84	19.92	15.17	13.86
Receivables	0.27	0.17	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	25.36	21.36	15.89	14.91

	2023	2024	2025	Q'26
Payables	0.21	0.53	0.17	0.28
ST’ Debt	—	—	—	—
Other	—	—	—	—
	2.03	2.50	1.97	1.75

in millions of $

Compound Annual Growth

	10y	5y	3y
Sales	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡
Cash Flow	‡‡‡	‡‡‡	‡‡‡
Earnings	‡‡‡	‡‡‡	‡‡‡
Book Value	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡

Revenue

	Jan	Apr	Jul	Oct	Year
’26	—	—	—	—	—
’23	—	0.21	—	—	0.21
’21	0.51	—	—	0.00	0.51
’19	—	0.25	—	—	0.25
’18	—	0.75	0.36	0.00	1.11
’17	—	—	0.36	—	0.36

in millions of $

Operating Cash Flow

	Jan	Apr	Jul	Oct	Year
’26	(2.61)	(1.74)	(1.77)	—	—
’25	(2.90)	(1.50)	(1.51)	(1.25)	(7.17)
’24	(2.31)	(1.46)	(2.64)	(0.93)	(7.33)
’23	(1.99)	(0.81)	(1.44)	(1.97)	(6.21)
’22	(1.20)	(2.31)	(1.40)	(1.59)	(6.49)
’21	(1.17)	(1.24)	(1.48)	(1.04)	(4.94)
’20	(1.91)	(1.56)	(1.29)	(1.41)	(6.18)

in millions of $

Free Cash Flow

	Jan	Apr	Jul	Oct	Year
’26	(2.61)	(1.74)	(1.77)	—	—
’25	(2.90)	(1.50)	(1.51)	(1.25)	(7.17)
’24	(2.31)	(1.46)	(2.64)	(0.93)	(7.33)
’23	(1.99)	(0.81)	(1.44)	(1.97)	(6.21)
’22	(1.20)	(2.31)	(1.40)	(1.59)	(6.49)
’21	(1.13)	(1.24)	(1.48)	(1.04)	(4.90)
’20	(1.93)	(1.56)	(1.29)	(1.41)	(6.19)

in millions of $

EPS

	Jan	Apr	Jul	Oct	Year
’26	(0.08)	(0.07)	(0.08)	—	—
’25	(0.10)	(0.09)	(0.07)	(0.09)	(0.34)
’24	(0.10)	(0.10)	(0.10)	(0.09)	(0.39)
’23	(0.08)	(0.07)	(0.08)	(0.09)	(0.32)
’22	(0.13)	(0.12)	(0.09)	(0.12)	(0.45)
’21	(0.09)	(0.08)	(0.14)	(0.13)	(0.45)
’20	(0.13)	(0.12)	(0.11)	(0.81)	(0.45)

Target Price Range

High

‡‡‡‡‡

‡‡‡‡

Average

‡‡‡‡‡

‡‡‡

Low

‡‡‡‡‡

‡‡‡

Recommendation Rating

1
Buy

3
Hold

5
Sell

2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2028
‡‡‡‡	‡‡‡	‡‡‡‡	‡‡‡‡	‡‡‡‡	‡‡‡‡	2.30	2.75	2.15	2.07	—	—	—	Low Price
‡‡‡‡	‡‡‡	‡‡‡‡	‡‡‡	‡‡‡	‡‡‡‡	6.25	6.45	5.13	5.46	—	—	—	High Price
‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	5	5	5	4	—	—	—	Employees
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡‡‡	0.00	0.04	0.00	0.00	—	—	—	Revenue/Emp
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—	‡‡‡‡‡	—	0.21	—	—	—	—	—	Revenue
‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	‡‡‡	0.00%	100.00%	—	—	—	—	—	Gross Margin
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	(13.77)	(9.93)	(12.70)	(11.03)	—	—	—	EBT
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡‡‡	0.00%	(4,728.57%)	0.00%	0.00%	‡‡‡	‡‡‡	‡‡‡	EBT Margin
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	(13.77)	(9.93)	(12.70)	(11.03)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	Net Income
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	0.04	0.05	0.04	(0.11)	—	—	—	Depreciation
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡‡‡	0.00	0.01	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	Revenue/Sh
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	(0.45)	(0.32)	(0.39)	(0.34)	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	Earnings/Sh
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	(0.21)	(0.20)	(0.23)	(0.22)	—	—	—	Cash Flow/Sh
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	0.00	0.00	0.00	0.00	‡‡‡	‡‡‡	‡‡‡	Capex/Sh
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	(0.21)	(0.20)	(0.23)	(0.22)	—	—	—	Free CF/Sh
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	0.93	0.75	0.59	0.43	—	—	—	Book Value/Sh
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	30.37	30.98	31.90	32.45	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	Shares
‡‡‡	‡‡‡	‡‡‡	‡‡‡	—	‡‡‡	—	0.00	—	—	‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	PE Ratio
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—	‡‡‡‡‡	—	100.72	—	—	‡‡‡	‡‡‡	‡‡‡	PS Ratio
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—	‡‡‡‡‡	—	4.19	—	—	‡‡‡	‡‡‡	‡‡‡	PB Ratio
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—	‡‡‡‡‡	—	76.38	—	—	—	—	—	EV/Sales
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—	‡‡‡‡‡	—	(12.02)	—	—	—	—	—	EV/FCF
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	(6.49)	(6.21)	(7.33)	(7.17)	‡‡‡	‡‡‡	‡‡‡	Op' Cash Flow
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	—	—	—	—	‡‡‡‡‡	—	—	Capex
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	(6.49)	(6.21)	(7.33)	(7.17)	—	—	—	FCF
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	28.16	23.33	18.86	13.92	—	—	—	Working Cap'
‡‡‡‡‡	—	—	—	‡‡‡‡‡	‡‡‡‡‡	0.22	—	—	—	—	—	—	Total Debt
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	(29.47)	(23.84)	(19.92)	(15.17)	—	—	—	Net Debt
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	28.20	23.37	18.89	13.95	—	—	—	Sh' Equity
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	(40.78%)	(35.08%)	(53.29%)	(58.01%)	—	—	—	ROA
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡	‡‡‡	‡‡‡	0.00%	0.00%	0.00%	0.00%	—	—	—	ROIC
‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	‡‡‡‡‡	(43.18%)	(38.05%)	(59.41%)	(66.55%)	—	—	—	ROE

predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Anixa Biosciences (ANIX), a lean clinical-stage biotech with just 4-5 employees, is developing promising cancer vaccines through key partnerships like Moffitt Cancer Center. Despite persistent losses, lumpy milestone-driven revenue, and eroding cash reserves, the stock trades at deeply undervalued levels—analysts’ mean price target implies a whopping 237% upside (low 148%, high 396%), fueled by FDA Fast Track nods and positive early trial data for ovarian and breast cancer programs.

Fundamentals paint a high-risk picture: revenue has swung wildly from peaks over $1 million to zeros, net losses hover around $10-15 million annually with no profitability in sight, and working capital has shrunk 60% since 2021 amid heavy R&D burn. Yet, recent insider buying—$169,600 worth including CEO and directors doubling down—signals confidence, contrasting with dilution pressures and biotech volatility.

Analysts bet big on upcoming Phase 2 data and trial restarts, potentially mirroring mRNA vaccine successes, despite forecasts of deepening losses through 2028. With runway concerns and execution risks looming, ANIX tempts speculators eyeing 200%+ gains—monitor Q1 2026 updates for the next catalyst.

Read full commentary →

ANIXA BIOSCIENCES INC (ANIX) Latest News

6 Jul

4 , 8:30 AM

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date

Anixa Biosciences and Moffitt Cancer Center have advanced their ovarian cancer CAR-T clinical trial to the highest dose level administered to date. Escalation of the ovarian cancer CAR-T trial to the highest dose marks a pivotal step in ANIX's lead therapeutic program that can materially affect clinical data, regulatory path, and valuation.

29 Jun

3 , 8:45 AM

Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040

Anixa Biosciences has been granted its first Korean patent for its breast cancer vaccine, extending global protection through 2040. Korean patent extends ANIX breast cancer vaccine IP protection to 2040, supporting product positioning without altering overall trajectory.

26 Jun

4 , 9:10 AM

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium

Anixa Biosciences reported positive data from completed Phase 1 breast cancer vaccine trial and positive survival observations from ongoing CAR-T Phase 1 trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium. Positive Phase 1 oncology data signals clinical progress that can drive development momentum and investor sentiment.

1 Jun

3 PR Newswire, 9:00 AM

Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance

Anixa Biosciences receives Canadian Notice of Allowance for patent on ovarian cancer vaccine technology, strengthening international IP protection. Canadian patent allowance advances IP protection for core vaccine technology with moderate competitive benefit.

11 May

4 PR Newswire, 8:55 AM

Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy

Anixa Biosciences reports updated positive survival observations from its ongoing Phase 1 trial of Lira-cel, a CAR-T therapy for ovarian cancer. Positive Phase 1 survival data for lead ovarian cancer CAR-T candidate signals major clinical progress likely to drive stock gains and partnerships.

29 Apr

4 , 9:10 AM

Anixa Biosciences Announces Issuance of Mexican Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences announces issuance of a Mexican patent covering its breast cancer vaccine technology, strengthening global intellectual property protection for the NANOVAX platform targeting tumor-associated antigens in breast cancer prevention and treatment. Mexican patent issuance bolsters Anixa's IP for breast cancer vaccine, aiding potential partnerships, licensing, and market expansion in biotech.

14 Apr

4 www.marketbeat.com, 10:02 PM

Anixa Biosciences Highlights Lean Cash Burn, CAR-T Survival Signals, and Phase II Vaccine Plan at Conference

Anixa Biosciences reports lean cash burn, positive CAR-T survival signals from ongoing trials, and detailed plans for a Phase II cancer vaccine study during a conference presentation. Pipeline advancements to Phase II and positive CAR-T signals combined with strong cash position significantly boost investor sentiment and future prospects.

1 Apr

4 PR Newswire, 8:50 AM

Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing

Anixa Biosciences advances its breast cancer vaccine to Phase 2 trials after positive Phase 1 results; selects Cytovance for cGMP manufacturing. Progress to Phase 2 with positive Phase 1 data and manufacturing partnership represents a significant milestone for ANIX's core vaccine program, enhancing future prospects and market sentiment.

30 Mar

3 PR Newswire, 9:05 AM

Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer

Anixa Biosciences to present its ovarian cancer CAR-T therapy clinical trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer. Presentation at a major gynecologic oncology conference provides visibility for ANIX's CAR-T pipeline but lacks detailed trial outcomes or approvals.

13 Mar

3 www.marketbeat.com, 4:45 PM

Anixa Biosciences AGM: Shareholders Back Directors as CEO Highlights CAR-T, Vaccine Progress

Anixa Biosciences shareholders re-elected all directors at the AGM; CEO highlighted progress in CAR-T cell therapy for breast and ovarian cancers and advancement of nanoliposome vaccine from COVID-19 to ovarian cancer trials. CEO pipeline updates on CAR-T and vaccines offer moderate positive sentiment amid routine shareholder approvals.

9 Mar

4 PR Newswire, 8:30 AM

Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences Inc. (ANIX) received a Notice of Allowance from the Korean Ministry of Intellectual Property (MOIP) for a patent covering its breast cancer vaccine technology. Patent allowance in Korea fortifies ANIX's IP for breast cancer vaccine tech, boosting competitive edge and market sentiment.

10 Feb

4 www.marketbeat.com, 3:50 PM

Anixa Biosciences CEO Calls 2026 “Pivotal” as Breast Cancer Vaccine, Ovarian CAR-T Advance

Anixa Biosciences CEO highlighted 2026 as a crucial year for the company, focusing on advancements in a breast cancer vaccine and ovarian CAR-T therapy. These developments are expected to play a significant role in the company's future direction and potential market impact. The advancements in cancer therapies could significantly alter the company's trajectory and investor sentiment.

9 Feb

4 PR Newswire, 8:00 AM

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation

Anixa Biosciences Inc. reported positive patient survival observations in its CAR-T trial for ovarian cancer, indicating promising results. The company has also received regulatory approval to escalate dosing in the trial, which could enhance treatment efficacy and patient outcomes. Regulatory approval for dose escalation and encouraging survival data could significantly impact the company's future performance and investor sentiment.

8 Feb

3 Simply Wall St., 7:42 AM

Here's Why We're Not Too Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

Anixa Biosciences is facing cash burn concerns, but analysts believe the situation is manageable due to the company's strong financial position and ongoing partnerships. The firm has sufficient cash reserves to support its operations and development projects, which include innovative cancer therapies. Investors are reassured by the potential for future funding and strategic collaborations that could enhance the company's market position. The cash burn situation is concerning but manageable, indicating a moderate influence on the company's financial performance.

2 Feb

4 , 9:00 AM

Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization

Anixa Biosciences Inc. has received approval from the United States Adopted Names Council for a non-proprietary name for its CAR-T therapy. This approval is a crucial step towards the future commercialization of the therapy, which aims to treat various cancers. The company is focused on advancing its innovative cancer treatment solutions. Approval of a non-proprietary name is a significant regulatory milestone that can enhance commercialization prospects and investor confidence.

27 Jan

4 PR Newswire, 8:30 AM

Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences Inc. has received a Notice of Allowance from the Mexican Institute of Industrial Property (IMPI) for a patent related to its breast cancer vaccine technology. This patent is a significant step in the company's efforts to advance its innovative approach to cancer treatment, potentially enhancing its intellectual property portfolio and market position. The patent allowance is a significant strategic move that could enhance Anixa's competitive position and investor sentiment in the oncology market.

15 Dec

4 PR Newswire, 8:45 AM

Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic

Anixa Biosciences Inc. has announced the transfer of its Investigational New Drug (IND) application for a breast cancer vaccine from the Cleveland Clinic to its own management. This strategic move is aimed at advancing the development of the vaccine, which targets a specific protein associated with breast cancer. The transfer is expected to enhance Anixa's capabilities in clinical development and potentially expedite the vaccine's progress towards clinical trials. The transfer of the IND represents a significant strategic move that could enhance Anixa's development capabilities and impact its future market performance.

11 Dec

4 PR Newswire, 6:02 PM

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants

Anixa Biosciences Inc. announced positive results from a Phase 1 clinical trial for its investigational breast cancer vaccine, meeting primary endpoints and demonstrating an immune response in 74% of participants. The trial's success marks a significant step forward in the development of the vaccine, which aims to provide a new treatment option for breast cancer patients. Positive Phase 1 data indicates significant progress in vaccine development, potentially impacting future market performance and investor sentiment.

17 Nov

4 PR NewswireTipRanksMT NewswiresPharmaceutical TechnologyPharma VoiceMT NewswiresMT NewswiresMT Newswires, 8:15 AM

Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization

Anixa Biosciences Inc. has received approval from the World Health Organization (WHO) for the International Non-Proprietary Name (INN) of its CAR-T therapy. This approval is a significant milestone that paves the way for global recognition and future commercialization of the therapy, enhancing the company's position in the biopharmaceutical market. WHO approval for the INN of the CAR-T therapy is a major strategic move that could significantly enhance Anixa's market position and investor sentiment.

13 Nov

4 Simply Wall St., 1:05 PM

Top Penny Stocks To Watch In November 2025

ANIXA Biosciences Inc. is highlighted as a top penny stock to watch in November 2025 due to its innovative approaches in biotechnology and potential for significant growth. The company is focusing on developing treatments for various diseases, which could enhance its market position. Investors are encouraged to monitor ANIXA's progress and market developments closely, as the biotech sector remains dynamic and competitive. ANIXA's focus on innovative treatments and potential market growth could significantly impact its future performance.

12 Nov

4 PR NewswireInsider MonkeyPharma VoiceMT NewswiresInsider MonkeyFastCompanyMT NewswiresGuruFocus.com, 9:00 AM

Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s

Anixa Biosciences Inc. has been awarded a significant U.S. patent that extends its intellectual property protection for its breast cancer vaccine into the 2040s. This patent is crucial for the company's ongoing development of its vaccine, which aims to provide a novel approach to breast cancer treatment. The extended protection is expected to enhance Anixa's competitive position in the market and support its long-term strategic goals. The patent extension is likely to significantly impact Anixa's future performance and market positioning by securing its innovative breast cancer vaccine development.

5 Nov

4 Zacks, 9:40 AM

Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?

Anixa Biosciences (ANIX) has shown strong stock performance this year, outpacing many of its medical peers. The company is focused on developing innovative therapies, particularly in cancer treatment and infectious diseases. Recent advancements and strategic partnerships have contributed to its positive market sentiment, positioning it favorably within the biotech sector. Investors are closely monitoring its progress as it continues to navigate the competitive landscape of medical biotechnology. Significant advancements and strategic partnerships are likely to impact Anixa's future performance and investor sentiment.

4 PR Newswire, 8:55 AM

Anixa Biosciences Announces Execution of Data Transfer Agreement with Cleveland Clinic

Anixa Biosciences Inc. has entered into a data transfer agreement with Cleveland Clinic, which is expected to facilitate the exchange of critical data for ongoing research and development initiatives. This collaboration aims to enhance Anixa's capabilities in advancing its innovative cancer therapies and diagnostics. The partnership underscores Anixa's commitment to leveraging cutting-edge research to improve patient outcomes. The data transfer agreement with Cleveland Clinic is a significant strategic move that could enhance Anixa's research capabilities and market positioning.

20 Oct

4 PR Newswire, 8:25 AM

Anixa Biosciences Announces Issuance of Chinese Patent Covering Breast Cancer Vaccine Technology

Anixa Biosciences Inc. has announced the issuance of a Chinese patent for its breast cancer vaccine technology. This patent is a significant step in the company's efforts to advance its innovative approach to cancer treatment, potentially enhancing its competitive position in the biotechnology sector. The issuance of a patent in a major market like China is likely to significantly impact the company's future prospects and investor sentiment.

17 Oct

4 Zacks, 12:00 PM

Are You Looking for a Top Momentum Pick? Why ANIXA BIOSCIENCES INC (ANIX) is a Great Choice

ANIXA BIOSCIENCES INC (ANIX) is highlighted as a strong momentum pick due to its innovative approaches in biotechnology and promising developments in cancer therapies. The company is positioned well in the market, attracting investor interest and showing potential for significant growth. Analysts suggest that ANIX's advancements could lead to substantial returns, making it an appealing choice for investors seeking momentum stocks. ANIX's advancements in biotechnology and cancer therapies are likely to significantly impact its market performance and investor sentiment.

15 Oct

4 Simply Wall St., 2:04 PM

October 2025 Penny Stocks With Promising Potential

ANIXA Biosciences Inc. is highlighted as a promising penny stock for October 2025, with potential for significant growth due to its innovative approaches in biotechnology. The company focuses on developing therapies and vaccines, particularly in the areas of cancer and infectious diseases. Investors are encouraged to consider ANIXA for its strategic positioning and advancements in the biotech sector, which may lead to increased market interest and investment opportunities. ANIXA's focus on innovative therapies and vaccines positions it for significant market impact and investor interest.

7 Oct

4 PR Newswire, 8:30 AM

Anixa Biosciences Announces Completion of Final Patient Visit in Breast Cancer Vaccine Clinical Trial

Anixa Biosciences Inc. has completed the final patient visit in its clinical trial for a breast cancer vaccine. This milestone marks a significant step in the development of the vaccine, which aims to provide a new treatment option for breast cancer patients. The company is now focused on analyzing the trial data and preparing for the next stages of the vaccine's development. Completion of the final patient visit in a clinical trial is a significant milestone that could lead to major advancements in product development and market positioning.

22 Sep

4 , 8:05 AM

Cleveland Clinic to Present Final Results of Phase 1 Clinical Trial for Anixa Biosciences' Breast Cancer Vaccine at 2025 San Antonio Breast Cancer Symposium

Cleveland Clinic will present the final results of a Phase 1 clinical trial for Anixa Biosciences' breast cancer vaccine at the 2025 San Antonio Breast Cancer Symposium. This presentation is anticipated to provide critical insights into the vaccine's efficacy and safety, potentially influencing future development and commercialization efforts. The presentation of final trial results could significantly impact investor sentiment and the company's strategic direction in cancer treatment.

16 Sep

4 Simply Wall St., 2:05 PM

September 2025's Promising Penny Stocks To Watch

ANIXA Biosciences Inc. is highlighted as a promising penny stock to watch in September 2025, reflecting potential growth opportunities in the biotech sector. The company focuses on innovative solutions in the field of immunotherapy and vaccine development, which may attract investor interest. Market trends suggest a favorable environment for biotech investments, positioning ANIXA as a notable contender in this space. The company's focus on innovative immunotherapy and vaccine development could significantly influence its market performance and investor sentiment.

8 Sep

4 PR Newswire, 8:00 AM

Anixa Biosciences and Moffitt Cancer Center Complete Dosing of Fourth Cohort in Ovarian Cancer CAR-T Clinical Trial; Multiple Patients Surpassing Median Expected Survival

Anixa Biosciences Inc. and Moffitt Cancer Center have completed dosing of the fourth cohort in their CAR-T clinical trial for ovarian cancer. Notably, multiple patients have surpassed the median expected survival, indicating promising results in the trial's progress. The completion of the fourth cohort and positive patient outcomes could significantly enhance the company's prospects and investor sentiment.

Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Subscribe now

ANIXA BIOSCIENCES INC ANIX

We limit data available in the Overview Report for users who do not have Powerpack

Insider Decisions

Capital & Financial Ratios

Dividends

Assets vs Liabilities

Compound Annual Growth

Revenue

Operating Cash Flow

Free Cash Flow

EPS

Target Price Range

Recommendation Rating

Analyst Commentary (Summary)

ANIXA BIOSCIENCES INC (ANIX) Latest News

News by impact score

Fine-tune

6 Jul

29 Jun

26 Jun

1 Jun

11 May

29 Apr

14 Apr

1 Apr

30 Mar

13 Mar

9 Mar

10 Feb

9 Feb

8 Feb

2 Feb

27 Jan

15 Dec

11 Dec

17 Nov

13 Nov

12 Nov

5 Nov

20 Oct

17 Oct

15 Oct

7 Oct

22 Sep

16 Sep

8 Sep

Powerpack

Watchlist

10 Years of Data

Screener

XLS Exports